# 1. Financial Performance ## A. Key Figures * **Revenue from Operations:** **₹174 Cr** Q1 FY26 (+74% YoY, +25% QoQ) · **₹139 Cr** Q4 FY25 * **PAT:** **₹51 Cr** Q1 FY26 (+218% YoY, +88% QoQ); **EPS: ₹4.13** * **EBITDA:** **₹79 Cr** Q1 FY26 (+220% YoY, +69% QoQ); **Margin: ~45%** * Operating Expenses: ₹77.14 Cr Q4 FY25 vs. ₹79.43 Cr prior quarter * **Business Mix:** **92% private**, **8% government** ## B. Revenue Growth * **Exceptional Top-Line Momentum:** Revenue surged on strong volume growth and improved bed occupancy, with no price increases, signaling robust organic demand. * **Revenue Mix Shift:** Panchkarma now drives majority of sales (54%), with private segment expanding rapidly amid deliberate drawdown in government exposure. * **Scalability Signal:** Monthly run rate of **₹60 Cr** supports trajectory toward **₹700 Cr** annual target, implying sustained growth momentum. * **Government Exposure De-Risked:** Reduced reliance on government sales to **8–9%** mitigates receivable risk, though **₹15–20 Cr** in pending collections expected within 3 months. ## C. Profit Margins * **Outsize Margin Expansion:** EBITDA margin reached ~45% on operating leverage and cost control, though current net margin of **29–30%** is deemed non-recurring. * **Sustainable Margin Target:** Management guiding to **20–25% net profit margin** over time, supported by rising occupancy and stable direct costs. * **High Medicine Gross Margin:** Medicine segment maintains **85% gross margin**, with **45%** passed to distribution network, highlighting channel economics. ## D. Operating Expenses * **Sharp Cost Optimization:** Opex fell to **₹14 Cr** despite adding ~470 beds, driven by lower marketing spend and vendor renegotiations. * **Efficiency Gains:** Reduced ad spend via patient-story content and centralized procurement (bedsheets, oils) delivered **3% QoQ expense reduction**, boosting profitability. * **Stable Direct Costs:** Medicine-related direct expenses held at **15%** (consumption at **9%**), expected to remain flat, supporting margin predictability. ## E. Cash Flow * **Government Receivables Cycle:** Payments typically delayed **4–6 months**, but **₹15–20 Cr** expected within next quarter, easing near-term cash flow. * **Minimal ESOP Impact:** Total ESOP expense to date **₹50–60 lakhs**, amortized over 5 years, resulting in **negligible annual dilution**. --- # 2. Bed Capacity & Utilization ## A. Key Figures * **Operational Beds:** **2,570** (up from 2,180) · **+390 beds added** * **Hospitals:** **55** (up from 50) · **NABH-Certified Hospitals:** **45** (up from 41) * **Long-Term Bed Target:** **7,000–10,000 beds** in 3–5 years (~**1,000 beds/year**) ## B. Operational Beds * **Accelerated Expansion:** Bed capacity growth outpaced plan, reaching **2,570 operational beds** ahead of schedule via partnerships with Ayurvedic colleges. * **Core Network Growth:** Expansion includes **55 hospitals** (5 new in 2025), with **45 NABH-certified**, reflecting improved quality and compliance standards. * **Scalable Footprint:** Despite minimal market share (<0.1% of India’s 1.9M beds), long-term ambition signals aggressive scaling potential. ## C. Occupancy Rates * **Stabilizing Utilization:** Recent occupancy stabilized at **~1,600 beds (~80% of operational capacity)**, indicating maturing performance despite short-term seasonality. * **Structural Occupancy Drivers:** Extended average stay (from **8–9 to 12–14 days**) and patient goodwill from **10% free treatment** initiative are boosting retention and organic demand. * **Transparency Enhancement:** Management confirms **bifurcation of occupancy data** into new vs. existing beds, improving analytical clarity. ## D. Expansion Targets * **Near-Term Focus on Utilization:** Priority shifted to **filling existing beds** rather than rapid asset expansion, emphasizing operational efficiency. * **Franchise Model Overhaul:** Old franchise network reduced from **60 to 36 clinics** and set for full phase-out; future growth to focus on **replicable, controlled models**. * **No Fixed Near-Term Target:** While long-term vision remains intact, **no firm bed target for next year** due to strategic review and stakeholder alignment. --- # 3. Product Launch & OTC Growth ## A. Key Figures * **Sales Growth:** 74% YoY in both services and product segments * **Online Sales:** ₹3 Cr monthly via jeenasikho.com * **Initial Orders:** 2,200 units sold in first hour; first batch sold out in 4 days * **Product Pricing:** ₹960, ₹1,900, and ₹2,400 variants launched * Revenue Target: ₹500 Cr OTC turnover expected within 1.5 to 2 years at 20% PAT margin ## B. New Product Rollout * **Strategic Expansion:** Launch of proprietary OTC platform "PET" in Lucknow on 22nd marks entry into Ayurvedic wellness, with **multi-state rollout planned within 1–2 months**. * **Product Differentiation:** New "Pet Liver Shuddhi Kit" targets root causes of digestive and liver disorders—**not just constipation**—positioned as a **non-habit-forming, multi-organ metabolic solution**. * **Clinical & Consumer Validation:** Product backed by clinical trials; early user feedback described as **"super-duper"**, with **25–26 video testimonials** from 650 users, including officials and ministers. * **Integrated Ecosystem:** OTC packaging will include clinic/hospital details to drive cross-referrals, creating a **vertically aligned care and commerce model**. * **Scalable Launch Model:** FOCO (Franchisee Owned, Company Operated) network to roll out in 15–20 days, avoiding capital-intensive infrastructure while accelerating reach. ## C. Sales & Distribution * **Pan-India Infrastructure:** Manufacturing and distribution localized by state (e.g., Punjab, UP, Maharashtra), with **regional language packaging** to enhance adoption. * **Digital-First Engagement:** Salesforce CRM, AI chatbots, and mobile apps for BP, diabetes, and mental health to support self-care; **health education sessions** to launch within 1–2 months. * **Low-Cost, High-Margin Go-to-Market:** Relies on **newspaper ads (Dainik Jagran, Amar Ujala), social media, and influencer outreach**—minimizing ad spend while preserving **20% PAT margin**. * **Distributor Momentum:** First super distributors onboarded in UP and Gujarat; **60+ state-level distributors invited** to Lucknow event, signaling strong channel confidence. ## D. Pipeline Development * **Robust R&D Foundation:** **12 clinical trials** registered with ICMR-CTRI (3 completed); **44–48 research papers** submitted, reinforcing evidence-based product claims. * **Broad Product Pipeline:** **15–16 new OTC products** in development for BP, diabetes, kidney, depression, and sexual health, with **6–7 to launch by March** and 15–20 in next year. * **Vertical Integration Plans:** Agreements with manufacturers in place; **targeting in-house production of 10–20 lakh units/month** and acquisition of a large manufacturing unit by next year. --- # 4. Hospital & College Partnerships ## A. Key Figures * **Revenue Share Models:** **INR2 lakhs rent + 6% revenue** (Sanskriti) · **INR5 lakhs rent + 7% revenue** (Saraswati Mohali) * Capital Efficiency: **INR1–1.5 lakhs** capex per bed with college partnerships (vs. **INR3–4 lakhs** standalone) * 2 clinics opened in Dubai/Abu Dhabi · 150-bed hospital launching next month (Vrindavan) · 100-bed hospital in Aurangabad launching in 3 months * **Profitability:** **INR10 lakhs profit** in 3 months from Nepal clinic * **Capacity Pipeline:** Targeting **7,000–10,000 new beds** over 3–5 years via college tie-ups ## B. Revenue Share Models * **Asset-Light Strategy:** No plans to own hospitals; focus on partnerships with institutions like Sanskriti and Saraswati Universities to maintain scalability and reduce capital intensity. * **Cost Advantage:** Access to **college-employed professors (50–60)** at lower cost enables significant operational savings. * **Scalable Franchise Model:** FOCO structure allows franchisee ownership with company-led operations, ensuring brand control and rapid replication. ## C. New Tie-Ups * **Technology Infusion:** New Mumbai partnership brings **HRC and blood-based biopsy** for non-invasive cancer screening, enhancing clinical differentiation. * **Talent Pipeline Secured:** Partnerships ensure **~100 trained doctors per college annually**, eliminating need for internal 3–6 month training programs. * **Favorable Deal Terms:** Aurangabad model features **zero rent + 7% revenue share**, setting benchmark for future accretive tie-ups. * **Franchise & Distributor Momentum:** **125 distributors/franchises** express super-distributor interest; **60 invited to strategic engagement event** in Lucknow. * **Leadership-Led Replication:** Manish Grover’s direct involvement in launching hospitals across **Chennai, Bangalore, Hyderabad, Assam** supports model transfer; team now being deployed for training. ## D. Geographic Expansion * **National Rollout Plan:** Expansion pipeline includes **south, east, west, and north** regions, with proven model set for replication across India. * **Untapped Bed Capacity:** Targeting **60,000 vacant beds near Ayurvedic colleges** as core growth vector, leveraging underutilized infrastructure. * **Scalability Proof Point:** From Chandigarh to **55 hospitals nationwide**, the model has demonstrated replicability across diverse geographies. --- # 5. Patient & Doctor Metrics ## A. Key Figures * **OPD Volumes:** **157,000** (FY23) → **252,000** (FY24) → **337,000** (FY25E) * **IPD Admissions:** **5,700** (2023) → **13,000** (2024) → **24,500** (2025E), with **8,600 in Q1 2025** * **Medicine Recipients:** **157,000** (2022–23) → **252,000** (2023–24) → **337,000** (2025E) * **Doctor Count:** **230** (2023) → **300** (2024) → **480** (2025E) → **532** (current) ## B. Admission Volumes * **Explosive Volume Growth:** OPD and IPD volumes surged with **strong double-digit to triple-digit YoY increases**, driven by high demand for private Panchakarma and chronic disease management. * **Shift Toward Preventive Care:** Wellness-focused visits without diagnosed conditions have grown sharply, now representing **10–12% of total visits**, up from 2–3%, signaling expanding market appeal. * **Critical & Late-Stage Patient Focus:** Treatment targets advanced-stage patients, including **Stage 4 cancer cases** dismissed by allopathic systems, with reported **long-term survival in 40–50 patients** and documented case studies of multi-year survival. * **Patient-Centric Model:** A **10-day trial policy** allows risk-free initiation of treatment, improving accessibility and trust, while structured **monthly follow-ups via dedicated teams** ensure outcome tracking. * **Goodwill-Driven Access:** **Free treatment for ~10% of patients** in financial distress is institutionalized, aimed at generating **lifelong word-of-mouth advocacy** and brand loyalty. ## C. OPD Footfall * **Cancer-Centric Demand:** Nearly **40% of OPD footfall is cancer-related**, with most patients having prior allopathic exposure, reinforcing positioning in complex, difficult-to-treat cases. * **High Satisfaction Despite Prognostic Limits:** **80% of patients report satisfaction**, though outcomes in the remaining 20% are constrained by **extremely critical or terminal entry conditions**. ## D. Medical Staff Growth * **Rapid Workforce Scaling:** Doctor headcount expanded rapidly to support volume growth, with the team now **fully operational and capable of independent execution and external representation**. --- # 6. Quality & Regulatory Risks ## A. Key Figures * **Collections:** **₹70–75 Cr** received from a ₹15 Cr, 3-month business ## B. Product Compliance * **End-to-End Quality Oversight:** Full in-house supervision of production with **onsite monitoring for 4–7 days** per batch and lab testing for every lot to ensure compliance and transparency. * **Clinical & R&D Rigor:** Treatment protocols guided by disease staging and outcomes research, with **dedicated doctors and R&D teams** continuously refining approaches based on case reviews. * **Philosophy-Driven Approach:** Emphasis on naturopathy and preventive care, with leadership advocating natural remedies over conventional medicine, citing organ toxicity risks. ## C. Government Payments * **Payment Delays Persist:** Outstanding receivables stem from systemic delays, with **12 government entities citing a new portal** to resolve issues within **2–3 months**. * **Selective Progress:** **Bihar and Maharashtra** have resumed Ayurveda bill processing; **CAPF business contracted** due to lack of dedicated payment infrastructure despite TGSS receiving timely payments. ## D. Clinical Claims * **Transparency in Treatment:** Patients sign consent forms acknowledging non-guaranteed outcomes, reinforcing ethical disclosure amid experimental therapy models. * **Controversial Efficacy Narrative:** Leadership suggests **10 lakh users** could lead to **full hospital occupancy** due to severe conditions like cancer and kidney failure, implying potential adverse public health impact. --- # 7. Guidance & Outlook ## A. Key Figures * **OTC Turnover Target:** **INR 500 Cr** in 1–2 years (20% PAT margin) * Annual Turnover Guidance: INR 700 Cr (excludes OTC and online) · PAT margin guidance 20-25% * **Monthly Run Rate:** **INR 60 Cr**, sustained in July–August with gradual growth expected * **Bed Expansion Plan:** **7,000–10,000 beds** targeted in **3–5 years** ## B. Revenue Targets * **Upside Beyond Guidance:** OTC and online revenues are incremental to the INR 700 Cr annual target, indicating a conservative outlook with embedded optionality. * **Execution Focus:** Management emphasizes sustaining and slightly increasing the current monthly run rate, supported by rising occupancy and imminent OTC launch. * **Selective Disclosure:** No OTC-specific revenue guidance provided through FY '26 due to evolving profitability visibility; outcomes framed as effort- and timing-dependent. ## C. Margin Expectations * **Sustainable Margin Target:** A **20%–25% PAT margin** is targeted for FY '26, deemed healthy for balancing patient affordability and business resilience. * **Occupancy-Driven Leverage:** Margin expansion expected primarily from higher occupancy rather than cost cuts, aligning with prior gross profit trends. * **No EBITDA Guidance:** EBITDA margin not formally guided; focus remains on gross and net profit dynamics observed historically. ## D. Growth Timeline * **Strategic Scale Ambition:** Aims to become India’s most respected Ayurveda-based healthcare platform, underpinned by bed capacity expansion and operational excellence. * **Public Sector Caution:** Government business expansion on hold pending improvements in payment systems and NHA portal functionality. * **Talent Incentive Planning:** New ESOPs in finalization stage, signaling long-term alignment and retention focus.